AI Insight
Hereditary angioedema due to C1 inhibitor deficiency (HAE-C1INH) causes recurrent, unpredictable swelling attacks that can last 3-5 days and result in significant morbidity and potential mortality if untreated. Unlike typical allergic angioedema, this condition does not respond to standard treatments such as antihistamines, corticosteroids, or epinephrine. Deucrictibant represents a novel oral on-demand treatment option for managing these attacks.
Why it matters
This development addresses a critical unmet need for patients with HAE-C1INH who currently lack effective standard emergency treatments. An oral on-demand medication could provide patients with more convenient and rapid access to treatment during unpredictable attacks, potentially reducing hospitalizations and improving quality of life.
Understand the Science
Hereditary angioedema due to a deficiency of C1 inhibitor (HAE-C1INH) is clinically characterised by recurrent, generally unpredictable attacks of angioedema.1 Untreated episodes are often severe and prolonged, lasting up to 3–5 days and engendering considerable morbidity and even mortality.2 Unlike angioedema associated with mast cell mediators, the swelling in HAE-C1INH does not respond to antihistamines, corticosteroids, or epinephrine.
Source: [Comment] Deucrictibant: a novel oral on-demand treatment for hereditary angioedema